Diurnal Fluctuations of Orexin-A and -B in Cynomolgus Monkey Cerebrospinal Fluid Determined by a Novel Analytical Method Using Antiadsorptive Additive Treatment Followed by Nanoflow Liquid Chromatography–High-Resolution Mass Spectrometry
Authors:
Open Access
- 31 January 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 14 (4) , 609-618
Abstract
Orexin-A (OXA) and -B (OXB) are involved in the regulation of multiple physiological functions including the sleep-wake states; therefore, it is critical to monitor their levels under various conditions. Unfortunately, the widely used radioimmunoassay has insufficient specificity for OXA. Although liquid chromatography-tandem mass spectrometry (LC-MS/MS) has higher specificity for OXA, previously reported OXA levels in human cerebrospinal fluid (CSF) measured using this technique are still inconsistent. Moreover, to the best of our knowledge, OXB has not been detected in the CSF. In this study, we established a novel method for OXA and OXB measurement. We noticed that OXA and OXB in the CSF was sticky; thus, citric acid and Tween 80 were used to prevent their nonspecific binding. Then, highly specific and sensitive nanoflow liquid chromatography-high-resolution mass spectrometry (nanoLC-HRMS) was used to measure OXA and OXB levels. Evaluation of the diurnal fluctuations of OXA and OXB in cisternal and lumbar CSF samples from cynomolgus monkeys revealed a sharp increase in the early light period, followed by a gradual increase to the maximum levels at the end of the light period, and then a sharp drop to the minimum levels during the early dark period. OXB levels were lower than OXA levels in cisternal CSF. Although basal OXA levels in individual monkeys showed substantial variations, the ratios between the maximum and minimum OXA levels of each monkey were similar. Our method for accurate OXA and OXB measurement should help improve our knowledge of orexin biology.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 23 references indexed in Scilit:
- From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluidScientific Reports, 2016
- Strategy to Improve the Quantitative LC-MS Analysis of Molecular Ions Resistant to Gas-Phase Collision Induced Dissociation: Application to Disulfide-Rich Cyclic PeptidesAnalytical Chemistry, 2014
- International Classification of Sleep Disorders-Third EditionChest, 2014
- Strategies to reduce aspecific adsorption of peptides and proteins in liquid chromatography–mass spectrometry based bioanalyses: An overviewJournal of Chromatography A, 2014
- The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy thresholdBMC Neuroscience, 2013
- Challenges in Urine Bioanalytical Assays: Overcoming Nonspecific BindingBioanalysis, 2010
- Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward SystemPharmacological Reviews, 2009
- Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null MiceNeuron, 2003
- Hypocretin (orexin) deficiency in human narcolepsyThe Lancet, 2000
- The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activityProceedings of the National Academy of Sciences, 1998